<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01251640</url>
  </required_header>
  <id_info>
    <org_study_id>14905</org_study_id>
    <secondary_id>2010-019588-12</secondary_id>
    <nct_id>NCT01251640</nct_id>
  </id_info>
  <brief_title>Combination With Gemcitabine in Advanced Pancreatic Cancer</brief_title>
  <acronym>BAGPAC</acronym>
  <official_title>A Multi-center, Phase I/II Study of BAY86-9766 in Combination With Gemcitabine in Patients With Locally Advanced Inoperable or Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, uncontrolled, Phase I/II study to evaluate safety and efficacy of BAY86-9766 plus
      gemcitabine in locally advanced, unresectable or metastatic pancreatic cancer.

      Phase I: Dose escalation study investigating 20, 30 and 50 mg BAY86-9766 plus gemcitabine
      (1000mg/m2); determination of maximum tolerated dose and recommended phase 2 dose.

      Phase II: Determination of response (RECIST 1.1; primary endpoint). Secondary endpoints:
      response duration, disease control rate, time to progression, progression-free survival,
      overall survival, safety and tolerability.

      Tumor assessments at Screening and than every 8 weeks.; Safety evaluations at Screening and
      weekly throughout the study; Safety follow-up visit 30 days after the last dose of study
      treatment; Survival follow up monthly for up to 8 month after LPFV.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2011</start_date>
  <completion_date type="Actual">August 1, 2013</completion_date>
  <primary_completion_date type="Actual">February 11, 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Dose Limiting Toxicities (DLT): Phase I</measure>
    <time_frame>From randomization up to the first 8 weeks of therapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor Response (Adjudicated Blinded Read Assessment): Phase II</measure>
    <time_frame>From start of treatment until 134 weeks assessed every 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor Response: Investigator Assessment: Phase I</measure>
    <time_frame>From start of treatment until 134 weeks assessed every 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control (DC): Phase I</measure>
    <time_frame>From start of treatment until 134 weeks assessed every 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control (DC): Phase II</measure>
    <time_frame>From start of treatment until 134 weeks assessed every 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR): Phase I</measure>
    <time_frame>From start of treatment until 134 weeks assessed every 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response: Phase II</measure>
    <time_frame>From start of treatment until 134 weeks assessed every 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP): Phase I</measure>
    <time_frame>From start of treatment until 134 weeks assessed every 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP): Phase II</measure>
    <time_frame>From start of treatment until 134 weeks assessed every 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS): Phase I</measure>
    <time_frame>From start of treatment until 134 weeks assessed every 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS): Phase II</measure>
    <time_frame>From start of treatment until 134 weeks assessed every 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS): Phase I</measure>
    <time_frame>From start of treatment until 134 weeks assessed every 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS): Phase II</measure>
    <time_frame>From start of treatment until 134 weeks assessed every 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY86-9766+Gemcitabine</intervention_name>
    <description>Phase I: 40 mg/day (20 mg twice daily), 60 mg/day (30 mg twice daily, 100 mg/day (50 mg bid) dependent on safety/tolerability Phase II: Recommended Phase II dose (RP2D) dependent on the results of the Phase I part of this study Route of administration: Oral, twice daily (bid) in combination with gemcitabine 1000 mg/m2 Intravenous infusion over 30 minutes weekly for seven out of eight weeks (Cycle 1); followed by 1000 mg/m2 Intravenous infusion over 30 minutes weekly for three out of four weeks (Cycle 2 and subsequent)</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients ≥18 years of age

          -  Histological or cytologically confirmed locally advanced, inoperable or metastatic
             pancreatic adenocarcinoma not amenable to curative radiotherapy or surgery

          -  Patients must have at least one uni-dimensional measurable lesion by CT or MRI
             according to RECIST, Version 1.1

          -  Resolution of all acute toxic effects of any prior local treatment to Common
             Terminology Criteria for Adverse Events (CTCAE) Grade &lt;/= 1

          -  Eastern Cooperative Oncology Group performance status (ECOG PS) &lt;/= 2

          -  Patient has cardiac function, within normal range, as measured by an echocardiogram

        Exclusion Criteria:

          -  Known history of, or symptomatic metastatic brain or meningeal tumors

          -  History of cardiac disease

          -  Active clinically serious infections

          -  Clinically significant (ie. symptomatic) peripheral vascular disease

          -  Pregnant or lactating women; women of childbearing potential not employing adequate
             contraception

          -  Use of strong inhibitors or inducers of CYP3A4

          -  Prior systemic therapy for metastatic or locally advanced, unresectable pancreatic
             cancer, or other malignancy

          -  Previous gemcitabine or 5-fluorouracil (5-FU) given concurrently as radiosensitizers
             to radiation therapy in adjuvant intention if given within 6 months from start of
             study treatment

          -  Thrombotic or embolic events such within 6 months prior to start of study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsfield</city>
        <state>Massachusetts</state>
        <zip>01201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <zip>656 53</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>CLERMONT-FERRAND Cedex 1</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heilbronn</city>
        <state>Baden-Württemberg</state>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <zip>35033</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brescia</city>
        <state>Lombardia</state>
        <zip>25124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ancona</city>
        <state>Marche</state>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oslo</city>
        <zip>0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <zip>15-027</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>WC1E 6BT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe</description>
  </link>
  <link>
    <url>https://clinicaltrials.bayer.com/</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 8, 2010</study_first_submitted>
  <study_first_submitted_qc>December 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2010</study_first_posted>
  <last_update_submitted>November 11, 2018</last_update_submitted>
  <last_update_submitted_qc>November 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreatic cancer,</keyword>
  <keyword>MEK-inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

